Michael Kuczewski

Michael has more than two decades of experience in the biotechnology industry, and a proven track record of leadership in process and analytical development, technology transfer, cGMP manufacturing, and CMC strategy. Most recently, Michael served as Vice President of CMC at Kelonia Therapeutics, where he led a team responsible for developing and scaling biomanufacturing processes. During his tenure, Michael played a key role in advancing Kelonia’s lead in vivo CAR-T candidate towards the clinic and established and executed a collaboration to develop another candidate with Astellas. Michael’s extensive experience spans both early- and late-stage gene therapy programs, and he has deep and valuable regulatory strategy expertise. Prior to his time at Kelonia, Michael held roles of increasing responsibility at 2Seventy bio and bluebird bio, where he played a pivotal role as CMC lead for the Abecma CAR-T program, guiding it from IND-enabling work to BLA approval. Michael holds a B.S. in Chemical Engineering from Worcester Polytechnic Institute.